<DOC>
	<DOCNO>NCT02295774</DOCNO>
	<brief_summary>Single Centre , open label assignment phase II clinical study . To evaluate effect oral 200mg Methylene Blue tablet ( administer 8x25mg ) prior endoscopy double strand DNA break colonic biopsy sample assess histone gamma H2AX analysis , compare control biopsy .</brief_summary>
	<brief_title>Effect Oral Administration Methylene Blue MMX Tablets Double Stranded DNA</brief_title>
	<detailed_description>Primary Objective : To evaluate effect oral 200 mg Methylene Blue MMX® tablet , ( administer 8 x 25 mg ) , prior endoscopy , double-stranded DNA break colonic biopsy sample assess histone γH2AX analysis , compare control biopsy collect standard white light colonoscopy without prior use Methylene Blue MMX® . Secondary Objectives : To evaluate safety tolerability oral Methylene Blue MMX® tablets.. To evaluate stain score colonoscopy obtain oral Methylene Blue MMX® tablet . Time reach caecum colonoscopy withdrawal time caecum exit .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Males female , age 18 75 . Outpatients schedule screen surveillance colonoscopy Subjects must identify clinical requirement second colonoscopy within 2weeks initial colonoscopy . Women childbearing potential must use least one reliable method contraception , surgically sterilise abstinent . For female subject , negative serum pregnancy test require Methylene Blue MMX® tablet dispense subject . Post menopausal patient need period great 1year since last menstrual period . Subjects must able comprehend full nature purpose study , include possible risk side effect . Subjects must able cooperate investigator comply requirement entire study . Signed write informed consent prior inclusion study . No Pregnant lactate woman , woman undergo fertility treatment . No previous medical history , suspect hypersensitivity Methylene Blue and/or formulation ingredient . No previous medical history , suspect hypersensitivity PEG base bowel cleanse preparation and/or formulation ingredient . No previous medical history gastrointestinal obstruction perforation , toxic megacolon , major colonic resection , severe diverticulitis , heart failure ( Class III IV ) , serious cardiovascular disease . No ALT , AST , GGT , Bilirubin , Creatinine Urea great 2.5 x upper limit normal , base local laboratory test . No clinical alarm symptom history anaemia ( previously record haemoglobin le 10mg/dL ) frank blood stool within last 30 day prior enrolment . No known deficiency glucose6phosphate dehydrogenase . No known deficiency NADPH reductase . No treatment within 5 week prior randomisation Fluoxetine ( Prozac ) . No concurrent treatment , previous treatment within 2 week prohibit psychiatric medication may interact Methylene Blue list Prohibited Medications section ; Selective Serotonin Reuptake Inhibitors ( SSRI ) , SerotoninNorepinepherine Reuptake Inhibitors ( SNRI 's ) , list Tricyclic antidepressant Monoamine oxidase A inhibitor . No concurrent treatment anticoagulant , antiaggregants , induce INR &gt; 1.5 . No current enrolment clinical trial , previous enrolment clinical trial within last 30 day . No medical condition investigator opinion would make administration study drug procedure hazardous subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>